Glenmark Pharmaceuticals S.a.

Ichnos Sciences Sa

Sanofi

Novartis Ag

Darko Skegro

Stanislas Blein

Samuel Hou

Romain Ollier

Rami Lissilaa

Jonathan Albert Back

Paul Wassmann

Regis Cebe

Antoine Attinger

Martin Bertschinger

Christophe Debonneville

Sebastien Irigaray

The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.

CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production

The present invention describes hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.

Production of T cell retargeting hetero-dimeric immunoglobulins

The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.

The present invention provides heterodimeric antibodies and fragments thereof and methods for their preparation, wherein the pairing of heavy and light chains has been improved. Interface residues were mutated such that each light chain strongly favoured its cognate heavy chain when two different heavy chains and two different light chains were co-transfected and co-expressed in the same cell to assemble a functional, heterodimeric antibody or fragment thereof.

Engineered heterodimeric proteins

The invention relates to antibodies directed to &#x3b1;2&#x3b2;1 integrin and their uses, including humanized anti-alpha 2 (&#x3b1;2) integrin antibodies and methods of treatment with anti-&#x3b1;2 integrin antibodies. More specifically the present invention relates to humanized anti-&#x3b1;2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.

Fc variant antibodies and their uses

The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.

Hetero-dimeric immunoglobulins

The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.

Antibodies that bind to TL1A and their uses

The invention relates to antibodies directed to &#x3b1;2&#x3b2;1 integrin and their uses, including humanized anti-alpha 2 (&#x3b1;2) integrin antibodies and methods of treatment with anti-&#x3b1;2integrin antibodies. More specifically the present invention relates to humanized anti-&#x3b1;2 integrin antibodies comprising a heavy chain variable region, a light chain variable region, a human light chain constant region and a variant human IgG1 heavy chain constant region which exhibit altered effector function.

Anti-alpha2 integrin antibodies and their uses

The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 28, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 29; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 30, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 31 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 32.

Growing community of inventors

La Chaux-de-Fonds, Switzerland

Darko Skegro